Item 7.01 Regulation FD Disclosure.

On January 9, 2023, Eledon Pharmaceuticals Inc. (the "Company" or "Eledon") issued a press release, which provided a business and pipeline update. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Also on January 9, 2023, the Company updated its investor presentation, which is used from time to time to conduct meetings with investors, stockholders and analysts. The investor presentation will also be available on the investor page of the Company's website at ir.eledon.com/investor-relations. A copy of the presentation is filed as Exhibit 99.2 and incorporated by reference herein.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1 and Exhibit 99.2) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the "Securities Act"), unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or incorporates it by reference into a filing under the Securities Act or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description 99.1 Press Release Issued on January 9, 2023 99.2 Corporate Presentation by the Company for January 2023 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses